SymbioCellTech, LLC
Travis Manning is a seasoned C-level executive with extensive experience in operational leadership and business development across various industries. Currently serving as Chief Operating Officer at SymbioCellTech, LLC, since June 2022, Travis Manning has focused on establishing business stability and fiscal transparency for the biopharmaceutical company. As Chief Revenue Officer at Extreme Auto Group since February 2020, Travis Manning has implemented cost control measures and optimized supply chain processes. Previous roles include Acting COO and Business Development lead at EverWoke, COO & Sales Manager at Verisave, and VP of Sales/Founder at JTP & Associates, where strategic business consulting yielded substantial financial recoveries for numerous sectors. Early career experience includes managing national hospital sales at Ingenix. Travis Manning holds a Bachelor of Science in Business Finance from the University of Utah, obtained between 1998 and 2000.
This person is not in any offices
SymbioCellTech, LLC
SymbioCellTech is a biotechnology company that has developed a patented, proprietary therapy to cure insulin-dependent Type I diabetes Mellitus (T1DM), which is commonly referred to as Type 1 or juvenile onset diabetes. In summary it is been shown that through an intra-abdominal administration of SymbioCellTech Neo-Islets™ (NIs; a cellulartherapeutic) has been shown in multiple animal models of Type 1 Diabetes to result in long-term glucose control with reduced or no need for insulin injections, and with no need for toxic antirejection drugs. The durable blood glucose control along with the absence of an immune response demonstrate that NIs provide protection from autoimmune attacks that ordinarily destroy insulin-producing cells in Type 1 Diabetes, and provide an endogenous and physiologic source of insulin.